Pulmatrix (PULM) Net Cash Flow (2013 - 2026)
Pulmatrix (PULM) posted Net Cash Flow of -$67000.0 for Q1 2026, up 90.51% sequentially from -$706000.0 in Q4 2025, and up 96.3% YoY from -$34130.7 in Q1 2025.
Pulmatrix (PULM) Net Cash Flow (2013 - 2026) Analysis & Trends
Pulmatrix has reported Net Cash Flow for 14 years, with the latest figure at -$67000.0 in Q1 2026.
- Quarterly Net Cash Flow rose 96.3% year-over-year to -$67000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.7 million (up 63.33% YoY) and the FY2025 annual result came in at -$5.4 million, up 51.12% from the prior year.
- Net Cash Flow advanced to -$67000.0 in Q1 2026 per PULM's latest filing, from -$706000.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at -$67000.0 in Q1 2026 and troughed at -$6.3 million in Q1 2022.
- A 5-year average of -$3.0 million and a median of -$2.9 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2026: Net Cash Flow plunged 385.59% in 2022, then soared 96.3% in 2026.
- Over 5 years, Net Cash Flow stood at -$5.1 million in 2022, then soared by 54.18% to -$2.3 million in 2023, then jumped by 45.55% to -$1.3 million in 2024, then soared by 44.01% to -$706000.0 in 2025, then surged by 90.51% to -$67000.0 in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$67000.0, -$706000.0, and -$1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | -1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.16 Mn |
| Jun 30, 2026 | -1.16 Mn |
| Mar 31, 2026 | -67,000.00 |
| Mar 31, 2026 | -67,000.00 |
| Dec 31, 2025 | -706,000.00 |
| Dec 31, 2025 | -706,000.00 |
| Sep 30, 2025 | -1.03 Mn |
| Sep 30, 2025 | -1.03 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -1.81 Mn |
| Mar 31, 2025 | -1.81 Mn |
| Dec 31, 2024 | -1.26 Mn |
| Dec 31, 2024 | -1.26 Mn |
| Sep 30, 2024 | -3.06 Mn |
| Sep 30, 2024 | -3.06 Mn |
| Jun 30, 2024 | -3.92 Mn |
| Jun 30, 2024 | -3.92 Mn |
| Mar 31, 2024 | -2.87 Mn |
| Mar 31, 2024 | -2.87 Mn |